Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (Nasdaq: TBPH) announces that it has entered into a definitive agreement pursuant to which Zymeworks Inc. will acquire the Company for $17.00 per share in cash, representing an equity value of approximately $929 million. In addition to the cash consideration, Theravance Biopharma shareholders will receive a CVR entitling them to 80% of net proceeds realized from any future license, divestiture or other monetization of ampreloxetine over the next ten years, with the remaining 20% to Zymeworks.
Read the full article: Theravance Biopharma Enters into Definitive Agreement to Be Acquired by Zymeworks for $17.00 per Share in Cash Plus a Contingent Value Right //
Source: https://www.prnewswire.com/news-releases/theravance-biopharma-enters-into-definitive-agreement-to-be-acquired-by-zymeworks-for-17-00-per-share-in-cash-plus-a-contingent-value-right-302813088.html